Therefore, according to the clinical and pathological characteristics of breast cancer patients, we established two main groups due to limited size of our sample: the Luminal group (Luminal A, Luminal B, and Luminal/Her2+ subtypes), which encompassed 25% (13/52) of patients with BrM, 70.6% (24/34) with NBrM and 85.3% (104/122) of WoM patients; and the non-Luminal group (TN and Her2-enriched subtypes), encompassing 75% (39/52) of patients with BrM, 29.4% (10/34) with NBrM, and 14.7% (18/122) of WoM patients. Here, ERBB2 is linked to breast cancer.